Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients

International Journal of STD and AIDS

Volumn 22, Issue 11, 2011, Pages 665-670

  Anekthananon, T ^a   Manosuthi, W ^b   Chetchotisakd, P ^c   Kiertiburanakul, S ^d   Supparatpinyo, K ^e   Ratanasuwan, W ^a   Pappas, P G ^f   Filler, S G ^g   Kopetskie, H A ^h   Nolen, T L ⁱ   Kendrick, A S ^j   Larsen, R A ^k  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Bamrasnaradura Infectious Diseases Institute   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Faculty of Medicine Chiang Mai University   (Thailand)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g HARBOR UCLA MEDICAL CENTER   (United States)

^h Rho Federal Systems Division Inc   (United States)

ⁱ RTI INTERNATIONAL   (United States)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

AIDS; Cryptococcosis therapy; Cryptococcus neoformans; HIV; Meningitis; Prognostic factors

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ARTICLE; CEREBROSPINAL FLUID CULTURE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; THAILAND; TREATMENT OUTCOME; UNITED STATES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; FLUCONAZOLE; HIV INFECTIONS; HUMANS; MENINGITIS, CRYPTOCOCCAL; PROGNOSIS; SURVIVAL ANALYSIS; THAILAND; TREATMENT OUTCOME; UNITED STATES;

EID: 81355153736     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2011.010538     Document Type: Article

References (23)

1. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas. Clin Infect Dis 2003;36:789-94
2. Epidemiological Information Section, Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health. Annual Epidemiological Surveillance Report. See http://203.157.15.4/Annual/ANNUAL2550/Part1/2650_AIDS.doc (last checked 14 January 2009)
3. Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, et al. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect 2001;43:226-33
4. Sloan D, Dlamini S, Paul N, Dedicoat M. Treatment of Acute Cryptococcal MeningitisiIn HIV Infected Adults, with an Emphasis on Resource-limited Settings (Review). London: The Cochrane Library, 2008. See http://www.thecochranelibrary.com/ (last checked 14 January 2009)
5. Van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21
6. Lortholary O, Poizat G, Zeller V, et al. Long-term outcome in AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006;20:2183-91
7. CDC, HIVMA/IDSA. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents, See http://AIDSinfo.nih.gov (last checked 14 January 2009)
8. Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. CID 2009;48:1784-86
9. SAS-Institute. SAS/STAT User's Guide, version 9.1. Cary, NC: SAS Institute, 1999
10. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-31
11. Larsen RA, Leal ME, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990;113:183-87
12. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-45
13. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med 1974;80:176-81
14. Graybill JR. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. CID 2000;30:47-54
15. Heyderman RS, Gangaidzo IT, Hakim JG, et al. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis 1998;26:284-89
16. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-67
17. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326:83-89
18. McCarthy KM. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006;20:2199-206
19. Robinson PA, Bauer M, Leal MAE, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999;28:82-92
20. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008;46:1694-701
21. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321:794-99
22. Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. CID 2009;49:702-09
23. Chottanapund S, Singhasivanon P, Kaewkungwal J, et al. Survival time of HIV-infected patients with cryptococcal meningitis. J Med Assoc Thai 2007;90:2104-11